Ovid Therapeutics OVID Institutional Ownership

Updated Oct 11, 2026

Ovid Therapeutics Inc. (NASDAQ:OVID) was held by 131 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Their combined stake equaled 74.45% of outstanding shares in Q2 2026, up from 62.81% in Q1 2026.
• Total shares held in OVID rose 39.91% from Q1 2026; the number of holders rose 89.86% from Q2 2025.
• Looking at the 131 holders of OVID individually, 80 added to their positions, 27 reduced their stakes and 24 left their positions unchanged.
• The aggregate institutional position in Ovid Therapeutics was 147Mn shares at the end of Q2 2026, up 41.94Mn from the prior quarter and up 111.05Mn from a year earlier.
• Jupiter Topco LLC held the largest position in OVID at 20.74Mn shares as of June 30, 2026, or 10.50% of shares outstanding.
• Among existing holders, the largest additions to Ovid Therapeutics in Q2 2026 came from BlackRock, Inc. (+9.29Mn shares), State Street Corp (+7.38Mn shares), ADAR1 Capital Management, LLC (+2.87Mn shares), Geode Capital Management, LLC (+2.75Mn shares) and Vanguard Capital Management LLC (+2.5Mn shares).
• Holders that trimmed the most shares of Ovid Therapeutics in Q2 2026 while keeping a position were Saturn V Capital Management LP (-3.5Mn shares), Ally Bridge Group (NY) LLC (-2.19Mn shares), Susquehanna International Group, LLP (-1.88Mn shares), Millennium Management LLC (-1.46Mn shares) and Renaissance Technologies LLC (-998.8K shares).
• Per Business Quant, the top 10 investors in OVID for the quarter ended June 30, 2026 were Jupiter Topco LLC (20.74Mn shares), Eventide Asset Management, LLC (11.81Mn shares), BlackRock, Inc. (10.82Mn shares), Ra Capital Management, L.P. (10.5Mn shares), Affinity Asset Advisors, LLC (10.14Mn shares), State Street Corp (7.9Mn shares), Vanguard Capital Management LLC (7.76Mn shares), ADAR1 Capital Management, LLC (7.42Mn shares), Balyasny Asset Management L.P. (6.72Mn shares) and Adage Capital Partners GP, L.L.C. (6.16Mn shares).